OBSE.F Stock Overview
A biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
ObsEva SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0001 |
| 52 Week High | US$0.40 |
| 52 Week Low | US$0.000001 |
| Beta | 6.74 |
| 11 Month Change | 9,900.00% |
| 3 Month Change | 0% |
| 1 Year Change | -99.75% |
| 33 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Shareholder Returns
| OBSE.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 2.5% | 2.2% |
| 1Y | -99.8% | 16.1% | 31.6% |
Return vs Industry: OBSE.F underperformed the US Biotechs industry which returned 16.1% over the past year.
Return vs Market: OBSE.F underperformed the US Market which returned 31.6% over the past year.
Price Volatility
| OBSE.F volatility | |
|---|---|
| OBSE.F Average Weekly Movement | 8,443.7% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: OBSE.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: OBSE.F's weekly volatility has decreased from 197587% to 8444% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 15 | Fabien de Ladonchamps | www.obseva.com |
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women’s reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. ObsEva SA was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA Fundamentals Summary
| OBSE.F fundamental statistics | |
|---|---|
| Market cap | US$11.72k |
| Earnings (TTM) | US$7.92m |
| Revenue (TTM) | US$19.64m |
0.0x
P/E Ratio0.0x
P/S RatioIs OBSE.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OBSE.F income statement (TTM) | |
|---|---|
| Revenue | US$19.64m |
| Cost of Revenue | US$10.71m |
| Gross Profit | US$8.93m |
| Other Expenses | US$1.01m |
| Earnings | US$7.92m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.068 |
| Gross Margin | 45.46% |
| Net Profit Margin | 40.34% |
| Debt/Equity Ratio | 0% |
How did OBSE.F perform over the long term?
See historical performance and comparison